Skip to main content

Table 6 Effect of Lucilia sericata larval products on Leishmania major amastigotes in in vitro conditions

From: The therapeutic effect of larval saliva and hemolymph of Lucilia sericata on the treatment of Leishmania major lesion in BALB/c mice946

Treatment

Dosages (ug/mL)

Amastigote L. major/peritoneal cell

Amastigote L. major/J774 cell-line

Time(h)

I%

V%

I %

V%

72 h

120 h

72 h

120 h

72 h

120 h

72 h

120 h

No-treatment control

0

73.7 ± 3.7

68.3 ± 4.1

100 ± 0

100 ± 0

61.3 ± 3.7

47 ± 2.9

100 ± 0

100 ± 0

Saliva

150

65.7 ± 5

35 ± 3.5

71.2 ± 4

50.5 ± 4.3

51 ± 3.9

31 ± 2.1

52.8 ± 4.2

47.5 ± 3.3

450

52.7 ± 3.6

28 ± 2.8

61.5 ± 3.7

44.2 ± 3.1

41 ± 1.8

23.3 ± 2.5

42.7 ± 1.4

37.3 ± 3.7

Hemolymph

150

59 ± 2.5

22.7 ± 1.8

65.7 ± 4.2

43.6 ± 2.9

47 ± 4.7

26.3 ± 3.6

41.4 ± 3.5

34.3 ± 4

450

41.7 ± 3.7

16.3 ± 4.4

43.7 ± 3.3

30.5 ± 1.8

29.3 ± 321

10 ± 1.1

31.7 ± 2.8

14.8 ± 2.7

Positive control Glucantime

50

51 ± 2.3

29.3 ± 3.8

59.2 ± 3.7

41 ± 1.8

43.8 ± 1.8

22 ± 1.5

51.7 ± 2.5

43.5 ± 1.4

100

38.3 ± 3.1

14 ± 2.16

46.2 ± 2.7

29 ± 2.8

31.7 ± 2.6

12.5 ± 1.2

37.1 ± 4

16.7 ± 1.8

  1. I% infection percentage, V% viability of amastigote percentage